AcceleDent® Aura Named Finalist in the 12th Annual American Business Awards Competition
HOUSTON, May 22, 2014 /PRNewswire/ -- OrthoAccel® Technologies, Inc. is pleased to announce that AcceleDent Aura is a finalist in the 12th Annual American Business Awards (ABA) Competition in the category of New Product of the Year - Health and Pharmaceuticals. Manufactured by OrthoAccel, AcceleDent® Aura is the first and only FDA-cleared, noninvasive medical device that speeds up orthodontic treatment by as much as 50 percent with just 20 minutes of daily use.
The ABAs, also known as The Stevie® Awards, honor and generate public recognition of achievements and positive contributions from every facet of business, such as new product development, marketing, information technology and web development, to name a few.
"As the leader of the accelerated orthodontic industry, we are thrilled that our product, AcceleDent Aura, has been recognized for its innovation," said Mike Lowe, president and CEO of OrthoAccel. "Never before has there been a noninvasive solution to accelerating orthodontic treatment and because of that, leading orthodontists are calling AcceleDent a game-changing product for the industry."
AcceleDent was one of more than 3,300 nominations submitted in the annual ABA competition, which is judged by 130 business professionals from varying industries. During preliminary judging, each entry is reviewed and rated by no fewer than five judges and it must receive an average score of at least 7 on a 10.0 scale to become a finalist.
Winners will be announced in September following the "People's Choice" open voting process, which allows the public to vote online for their favorite new product.
"AcceleDent is available in over 1,500 orthodontic locations across the U.S., so we encourage all of our orthodontists as well as their patients and staff to vote and help AcceleDent Aura win this national recognition," said Lowe. "We'll have plenty of reminders and notifications on our Facebook and Twitter pages when voting opens."
Voting will be conducted during July and August. For more information about the ABAs or to be notified when the voting process commences, voters can sign-up for alerts at http://www.stevieawards.com/pubs/awards/403_2610_19542.cfm.
Patients, orthodontists or staff members interested in learning more about AcceleDent can visit AcceleDent.com.
About OrthoAccel® Technologies, Inc.
Based in Houston, Texas, OrthoAccel® Technologies, Inc. is a privately owned medical device company engaged in the development, manufacturing and marketing of products to enhance dental care and orthodontic treatment. OrthoAccel developed and sells AcceleDent® Aura, the first FDA-cleared clinical approach to safely accelerate orthodontic tooth movement by applying gentle micropulses via SoftPulse Technology® as a complement to existing orthodontic treatment. More information can be found at www.acceledent.com and www.acceledent.co.uk or requested via email@example.com.
SOURCE OrthoAccel Technologies, Inc.